BlackRock Amends Twist Bioscience Stake, Signals Continued Confidence
Ticker: TWST · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1581280
| Field | Detail |
|---|---|
| Company | Twist Bioscience Corp (TWST) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
Related Tickers: TWST
TL;DR
**BlackRock still owns a chunk of Twist Bioscience, good sign for TWST!**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Twist Bioscience Corp (TWST) common stock as of December 31, 2023. This filing, Amendment No. 5, updates BlackRock's passive investment stake in the biological products company. This matters to investors because BlackRock, a major institutional investor, continues to hold a significant position in TWST, signaling ongoing confidence in the company's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
This filing shows that a major institutional investor, BlackRock, maintains a significant position in Twist Bioscience, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative risks for the company.
Analyst Insight
Investors should note BlackRock's continued passive stake as a sign of institutional confidence, but this filing alone doesn't provide new actionable insights on share percentage changes or future performance.
Key Numbers
- 90184D100 — CUSIP Number (identifies Twist Bioscience Corp's Common Stock)
- 5 — Amendment Number (indicates this is the fifth update to BlackRock's Schedule 13G filing for Twist Bioscience)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Twist Bioscience Corp (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 5 (number) — the specific amendment number of the filing
Forward-Looking Statements
- BlackRock will continue to hold a significant, passive stake in Twist Bioscience Corp. (BlackRock Inc.) — high confidence, target: next 12 months
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 5, filed under Rule 13d-1(b).
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager.
What is the subject company whose securities are being reported?
The subject company is Twist Bioscience Corp, identified by the CUSIP Number 90184D100.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023.
What is the business address of Twist Bioscience Corp?
Twist Bioscience Corp's business address is 681 Gateway Blvd., South San Francisco, CA 94080.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Twist Bioscience Corp (TWST).